Cilta-Cel Safety Profile in Multiple Myeloma: Adam D. Cohen, MD


The director of Myeloma Immunotherapy at University of Pennsylvania discussed ciltacabtagene autoleucel's safety profile.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Adam D. Cohen, MD, assistant professor of medicine and director, Myeloma Immunotherapy, University of Pennsylvania, to learn more about the safety profile of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma.

Cohen discussed safety data from the phase 2 CARTITUDE-2 study (NCT04133636). The study found that the main hematologic toxicities observed with cilta-cel were similar to those reported in the phase 1/2 CARTITUDE-1 trial (NCT03548207). These included neutropenia, anemia, and thrombocytopenia, according to Cohen. These toxicities are most often associated with lymphodepletion conditioning therapy, as well as the CAR T-cell therapy itself, Cohen explains.

The rates of grade 3/4 thrombocytopenia and anemia appeared to be less than what was reported on CARTITUDE-1, and prolonged grade 3/4 cytopenias also occurred less frequently; this may be because the CARTITUDE-2 study enrolled a less heavily pretreated population, Cohen concludes.

Related Videos
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
© 2024 MJH Life Sciences

All rights reserved.